Abstracts tagged "Infection"

Abstract Number: 0205 • ACR Convergence 2023
Changes in Serum Rheumatoid Factor Following Eradication of Hepatitis C Virus Infection with Interferon or Direct Antiviral Therapy
Jamie Chieh Lo¹, Ying-Nan Tsai², Cheng-Hao Tseng³, Yao-Chun Hsu⁴ and Song-Chou Hsieh⁵, ¹School of Medicine, I-Shou University, Kaohsiung, Taiwan, ²Department of Gastroenterology and Hepatology, E-Da Cancer Hospital, Kaohsiung, Taiwan, ³Division of Gastroenterology and Hepatology, E-Da Cancer Hospital, Kaohsiung, Taiwan, ⁴I-Shou University School of Medicine, E-Da Hospital Center of Liver Diseases, Kaohsiung, Taiwan, ⁵National Taiwan University Hospital, Taipei, Taiwan
Background/Purpose: Chronic hepatitis C virus (HCV) infection is associated with autoimmune extrahepatic manifestations including increased production of autoantibodies such as rheumatoid factor (RF). Prior to…
Abstract Number: 0680 • ACR Convergence 2023
Risk Factors for Hypogammaglobulinemia and Association with Relapse and Severe Infections in ANCA-Associated Vasculitis: A Retrospective Single-Centre Cohort Study
Johanne LIBERATORE¹, Yann Nguyen², Jerome HADJADJ³, Pascal Cohen⁴, Luc Mouthon⁵, Xavier Puéchal⁶, Loic Guillevin⁷ and Benjamin Terrier⁸, ¹Centre Hospitalier ANGOULEME, Angouleme, France, ²Department of Internal Medicine, Hôpital Beaujon, AP-HP, Clichy, France., Montmorency, France, ³Cochin Hospital, Paris, France, ⁴CHU Cochin, Paris, France, ⁵Hopital Cochin - Paris University, Paris, France, ⁶National Referral Center for Rare Systemic Autoimmune Diseases, Paris, France, ⁷University Paris Descartes, Paris, France, ⁸Department of Internal Medicine, Hôpital Cochin, AP-HP, Paris, France
Background/Purpose: B-cell depletion induced by rituximab (RTX) in ANCA-associated vasculitis (AAV) is a risk factor for hypogammaglobulinemia. Aggregating data on the kinetics of gammaglobulin levels…
Abstract Number: 1445 • ACR Convergence 2023
SLESIS-R: An Improved Score for Prediction of Serious Infection in Patients with Systemic Lupus Erythematosus Based on the RELESSER Prospective Cohort
Iñigo Rúa-Figueroa¹, Maria Jesus Garcia de Yebenes², JULIA MARTINEZ BARRIO³, Maria Galindo-Izquierdo⁴, Jaime Calvo- Alén⁵, Antonio Fernandez-Nebro⁶, Raúl Menor-Almagro⁷, Eva Tomero Muriel⁸, Mercedes Freire González⁹, Clara Sanguesa Gomez¹⁰, Loreto Horcada¹¹, Ricardo Blanco¹², Esther Uriarte Isacelaya¹³, Maria J. García-Villanueva¹⁴, Javier Narvaez¹⁵, Jose Rosas¹⁶, Silvia Gómez-Sabater¹⁷, Clara Moriano Morales¹⁸, Jose Luis Andreu-Sánchez¹⁹, Vicente Torrente-Segarra²⁰, Elena Aurrecoechea Aguinaga²¹, Ana Pérez Gómez²², Javier Novoa Medina²³, Eva Salgado-Pérez²⁴, Nuria Lozano Rivas²⁵, Carlos Montilla-Morales²⁶, maria esther ruiz-lucea²⁷, Marta Arévalo Salaet²⁸, Carlota Iñíguez²⁹, Lorena Expósito³⁰, Mónica Ibáñez-Barceló³¹, Gema Bonilla³², Irene Carrión-Barberà³³, Celia Erausquin³⁴, Angela Pecondon-Español³⁵, Francisco Javier Toyos Sáenz de Miera³⁶, Tatiana Cobo³⁷, Alejandro Muñoz³⁸, Jorge Juan Fragio³⁹, Jose Eloy Oller⁴⁰, Beatriz Tejera Segura²³ and Jose-Maria Pego-Reigosa⁴¹, ¹Rheumatology, Hospital de Gran Canaria Doctor Negrin, Las Palmas de Gran Canaria, Spain, ²InMusc, Madrid, Spain, ³Rheumatology, Gregorio Marañon University Hospital, Madrid, Spain, ⁴Rheumatology, University Hospital of 12 de Octubre, Madrid, Spain, ⁵Rheumatology, Bioaraba Research Unit, Hospital Universitario Araba, Vitoria, Spain, ⁶Hospital Regional Universitario de Málaga, Malaga, Spain, ⁷Rheumatology, Hospital Jerez, Puerto De Santa María, Spain, ⁸Rheumatology, Hospital La Princesa, Madrid, Spain, ⁹Rheumatology department, Complexo Hospitalario Universitario A Coruña (CHUAC). Instituto de Investigación Biomédica A Coruña (INIBIC), A Coruña, Spain, ¹⁰Severo Ochoa Hospital, Madrid, Spain, ¹¹Hospital de Navarra, Pamplona, Spain, ¹²Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain, ¹³Rheumatology, University Hospital of Donosti, San Sebastián, Spain, ¹⁴Hospital Ramón y Cajal, Madrid, Spain, ¹⁵Hospital Universitario de Bellvitge, Barcelona, Spain, ¹⁶Hospital Marina Baixa, Alicante, Spain, ¹⁷Rheumatology Department, Dr. Balmis University General Hospital, Alicante. Institute for Health and Biomedical Research (ISABIAL), Alicante, Spain, ¹⁸Rheumatology, Hospital Universitario de León, León, Spain, ¹⁹Rheumatology, Hospital Universitario Puerta de Hierro, Majadahonda, Spain, ²⁰Department of Rheumatology, Hospital de Sant Joan Despí Moises Broggi,, Sant Joan Despí, Spain, ²¹Department of Rheumatology, Hospital Sierrallana, Torrelavega, Spain, ²²Rheumatology, Hospital Principe de Asturias, Alcalá de Henares, Spain, ²³Complejo Hospitalario Universitario Insular de Gran Canaria, Las Palmas de Gran Canaria, Spain, ²⁴Department of Rheumatology, University Hospital of Ourense, Ourense, Spain, ²⁵Department of Rheumatology, Hospital Clínico Universitario Virgen de la Arrixaca, Murcia, Spain, ²⁶Rheumatology, University Hospital of Salamanca, Salamanca, Spain, ²⁷Hospita de Basurto, Bilbao, Spain, ²⁸Rheumatology Department University Hospital Parc Taulí, Sabadell, Spain, ²⁹Hospital Lucus Augusti, Lugo, Spain, ³⁰Rheumatology Unit, Hospital Universitario de Canarias, San Cristóbal de La Laguna, Spain, ³¹Rheumatology, Hospital Universitari Son Llàtzer, Palma de Mallorca, Spain, ³²Department of Rheumatology, Hospital Clínico Universitario La Paz, Madrid, Spain, ³³Hospital del Mar, Barcelona, Spain, ³⁴Rheumatology Department Hospital Universitario de Gran Canaria Doctor Negrín, Las Palmas de Gran Canaria, Spain, ³⁵Hospital Miguel Servet, Zaragoza, Spain, ³⁶Hospital Virgen Macarena, Sevilla, Spain, ³⁷Department of Rheumatology, Hospital Universitario Infanta Sofía, Universidad Europea, Madrid, Spain, ³⁸Hospital universitario Virgen del Rocío, El Viso de Alcor, Spain, ³⁹Hospital General Universitario Valencia, Valencia, Spain, ⁴⁰Hospital Doctor Peset, Valencia, Spain, ⁴¹Rheumatology, Hospital do Meixoeiro, Vigo, Spain
Background/Purpose: Patients with systemic lupus erythematosus (SLE) have an increased risk of serious infections that varies with the severity of the disease, use of immunosuppressives,…
Abstract Number: 1935 • ACR Convergence 2023
Pre-exposure Prophylaxis with Tixegvimab/cilgavimab Is Effective in Limiting the Risk and Severity of COVID-19 in Patients with Auto Immune or Inflammatory Diseases at Increased Risk of Severe COVID-19
Marion THOMAS¹, Maeva MASSON², Raphaele Seror³, Samuel Bitoun⁴, Henry DUPUY⁵, Lazato ESTIBALIZ⁵, Christophe Richez⁶, Yannick ALLANORE⁷ and Jerome AVOUAC⁸, ¹HOPITAL COCHIN AP-HP, Service de Rhumatologie, Paris, France, ²CHU Toulouse, Toulouse, France, ³University Hospital Paris Saclay, Le Kremlin-Bicêtre, France, ⁴CHU Bicêtre APHP, Le Kremlin-Bicêtre, France, ⁵CHU Bordeaux, Bordeaux, France, ⁶Université de Bordeaux, Bordeaux, France, ⁷Université Paris Cité, Paris, France, ⁸Rheumatology A Department, Hôpital Cochin, AP-HP Centre - Université Paris Cité, Paris, France
Background/Purpose: Patients with autoimmune or inflammatory diseases treated with immunosuppressants such as anti-CD20 are at increased risk for severe COVID-19 and have a high probability…
Abstract Number: 2316 • ACR Convergence 2023
Effect of SARS-CoV2 Infection on Disease Flares in Patients with Systemic Lupus Erythematosus: A Case-control Study
Chi Chiu Mok¹, Chris Cheung², Chi Hung To³, Kar Li Kelly Chan⁴ and SAU MEI TSE⁵, ¹Tuen Mun Hospital, Hong Kong, Hong Kong, ²Rutonjee Hospital, Hong Kong, Hong Kong, ³Pok Oi Hospital, Hong Kong, Hong Kong, ⁴Tuen Mun Hospital, Shatin, China, ⁵Tuen Mun Hospital, Hong Kong, China
Background/Purpose: To study the effect of SARS-CoV2 infection on disease flares in patients with systemic lupus erythematosus (SLE).Methods: Patients who fulfilled the ACR or SLICC…
Abstract Number: 0206 • ACR Convergence 2023
Risk of Hepatitis B Virus Reactivation in Patients with Rheumatoid Arthritis Receiving JAK Inhibitor or IL-6 Inhibitor: A Systematic Review and Meta-Analysis
Akhil Sood, Janice Lin and Neha Shah, Stanford University, Palo Alto, CA
Background/Purpose: Due to the use of immunosuppressants, patients with rheumatic diseases are at increased risk for Hepatitis B virus (HBV) reactivation. B-cell depleting agents and…
Abstract Number: 0751 • ACR Convergence 2023
Recombinant Zoster Vaccination Among U.S. Veterans Receiving Immunosuppressive Medications 2017-2023
Sharon Abada¹, Jing Li¹, Gary Tarasovsky², Cherish Wilson³, Jinoos Yazdany¹, Mary Whooley¹ and Gabriela Schmajuk³, ¹University of California San Francisco, San Francisco, CA, ²San Francisco VA, San Francisco, CA, ³UCSF / SFVA, San Francisco, CA
Background/Purpose: Patients receiving immunosuppressive therapies are known to have a higher risk of herpes zoster and subsequent complications compared to the general population. The recombinant…
Abstract Number: 1479 • ACR Convergence 2023
Risk Factors for Human Papillomavirus Cervical Infection and Clearance in Patients with Systemic Lupus Erythematosus: The PAPILUP Study
Tiphaine Goulenok¹, Valentine Marie Ferre², Celine Mendes¹, Lea Dayan³, Margot Bucau¹, Fatima Farhi¹, Thomas Papo² and Karim Sacre², ¹Assistance Publique Hopitaux de Paris, Paris, France, ²Université Paris Cité, Paris, France, ³Maison de Sante les Epinettes, Paris, France
Background/Purpose: An impaired clearance of cervical human papillomavirus (HPV) related to inadequate immune responses may result in persistent infection and increase the risk to develop…
Abstract Number: 1967 • ACR Convergence 2023
Infectious Myopathies in an Urban Inflammatory Idiopathic Myopathy Cohort: Frequency and Impact on Disease Course and Treatment
Ana Valle¹, Talia Meisel¹, Xianhong Xie² and Shereen Mahmood³, ¹Montefiore Medical Center, Bronx, NY, ²Albert Einstein College of Medicine, Bronx, NY, ³Albert Einstein College of Medicine / Montefiore Medical Center, New York, NY
Background/Purpose: Over the last few decades, it has been established that multiple infections can mimic idiopathic inflammatory myopathies (IIM). HIV, HTLV-1, and Lyme disease are…
Abstract Number: 2348 • ACR Convergence 2023
Incidence of Infections Among Adult Patients with SLE Treated with Belimumab (BEL): Pooled Data from Three Open-Label Extension Studies over 11+ Years
Jinoos Yazdany¹, Kenji Oku², Luciana Seguro³, Paula Curtis⁴, Yoshifumi Inagaki⁵, Roger A. Levy⁶ and Andrea Doria⁷, ¹University of California, General Department of Medicine, Division of Rheumatology, San Francisco, CA, ²Kitasato University School of Medicine, Department of Rheumatology and Infectious Diseases, Kanagawa, Japan, ³Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Rheumatology Division, Universidade de Sao Paulo, São Paulo, Brazil, ⁴GlaxoSmithKline, R&D Biostatistics, Brentford, United Kingdom, ⁵GlaxoSmithKline, Global Medical Affairs, Brentford, United Kingdom, ⁶GlaxoSmithKline, Global Medical Affairs, Collegeville, PA, ⁷University of Padova, Rheumatology Unit, Department of Medicine, Padova, Italy
Background/Purpose: BEL-treated patients (pts) in clinical trials and long-term extension (LTE) studies1-7 experienced comparable incidence of infections versus those treated with standard therapy (ST) alone…
Abstract Number: 0207 • ACR Convergence 2023
Role of Pneumocystis Jirovecii Pneumonia Prophylaxis with Trimethoprim-Sulfamethoxazole Among Patients with Autoimmune Inflammatory Diseases Receiving High-Dose Glucocorticoids: A Systematic Review and Meta-Analysis
Athanasios Vassilopoulos¹, Stephanos Vassilopoulos¹, Fadi Shehadeh², Markos Kalligeros¹ and Eleftherios Mylonakis³, ¹Division of Internal Medicine, Warren Alpert Medical School of Brown University, Rhode Island Hospital, Providence, RI, ²Houston Methodist Research Institute, Houston, TX, ³Department of Medicine, Houston Methodist Hospital, Houston, TX
Background/Purpose: Available immunosuppressive treatments for autoimmune inflammatory rheumatic diseases (AIRD) might increase the risk for opportunistic infections, such as Pneumocystis jirovecii pneumonia (PJP). Prophylactic trimethoprim-sulfamethoxazole…
Abstract Number: 0752 • ACR Convergence 2023
Tuberculosis Screening Among New Users of a Biologic or Targeted Synthetic DMARD: Gaps in Coverage Overall and Among JAKi Initiators
Eric Roberts¹, Gabriela Schmajuk² and Jinoos Yazdany¹, ¹University of California San Francisco, San Francisco, CA, ²UCSF / SFVA, San Francisco, CA
Background/Purpose: Screening for latent tuberculosis (TB) is recommended prior to starting biologics or targeted synthetic DMARDs (b/tsDMARDs). With a growing number of these drugs available…
Abstract Number: 1500 • ACR Convergence 2023
Cumulative Infections by Week 52 Among Patients with SLE: A Summary of Data from Placebo-Controlled Belimumab Studies
Saira Sheikh¹, Kevin Withrop², Jinoos Yazdany³, Sandra Navarra⁴, Tatsuya Atsuma⁵, Paula Curtis⁶, Jose Miyar Olaiz⁷, Christine Henning⁸, Roger A. Levy⁹, William Stohl¹⁰ and Daniel Wallace¹¹, ¹University of North Carolina at Chapel Hill, Chapel Hill, NC, ²Oregon Health & Science University, Schools of Medicine and Public Health,, Portland, OR, ³University of California, General Department of Medicine, Division of Rheumatology, San Francisco, CA, ⁴University of Santo Tomas Hospital, Joint and Bone Center, Manila, Philippines, ⁵Hokkaido University, Department of Rheumatology, Endocrinology and Nephrology, Sapporo, Japan, ⁶GlaxoSmithKline, R&D Biostatistics, Brentford, United Kingdom, ⁷GlaxoSmithKline, Safety Evaluation and Risk Management, Brentford, United Kingdom, ⁸GlaxoSmithKline, US Medical Affairs, Durham, NC, ⁹GlaxoSmithKline, Global Medical Affairs, Collegeville, PA, ¹⁰University of Southern California Keck School of Medicine, Division of Rheumatology, Los Angeles, CA, ¹¹Cedars-Sinai Medical Center, Los Angeles, CA
Background/Purpose: Patients with SLE have a high risk of infections, which remains a common cause of mortality in this population.1 This infection risk can result…
Abstract Number: 2050 • ACR Convergence 2023
Variability in Vaccination Practices in Children with Rheumatic Diseases: Results of a Rheumatology Provider Childhood Arthritis and Rheumatology Research Alliance (CARRA)-wide Survey
Randal De Souza¹, Merav Heshin Bekenstein², Beth Rutstein³, Maria Schletzbaum⁴, Nora Singer⁵, Melanie Kohlheim⁶, vincent del gaizo⁷, Kelly Wise⁸, Melica Nikahd⁹, Guy Brock¹⁰, Rebecca Sadun¹¹, Monica Ardura¹, Vidya Sivaraman¹ and For The CARRA Registry Investgators⁷, ¹Nationwide Children's Hospital, Columbus, OH, ²Dana Children's Hospital of Tel Aviv Medical Center, Tel Aviv, Israel, ³Division of Rheumatology at Children's Hospital of Philadelphia, Philadelphia, PA, ⁴St. Louis Children’s Hospital / Washington University in St. Louis, Middleton, WI, ⁵The MetroHealth System at Case Western Reserve University School of Medicine, Cleveland, OH, ⁶Self, Granville, OH, ⁷CARRA, Inc, Washington, DC, ⁸Nationwide Children's Hospital, Hilliard, OH, ⁹Ohio State University, Columbus, OH, ¹⁰Dept. of Biomedical Informatics, Columbus, OH, ¹¹Duke University, Durham, NC
Background/Purpose: Immunocompromised children (ICC), including children with rheumatic diseases receiving immunosuppressive therapies (IST) are at increased risk of morbidity from vaccine-preventable infections. The 2022 American…
Abstract Number: 2377 • ACR Convergence 2023
The Impact of Chronologic versus Biologic Age on the Risk of Severe Infection, End-Stage Renal Disease, and Death in Older Adults with ANCA-Associated Vasculitis
Sebastian Sattui¹, Xiaoqing Fu², Claire Cook², Shruthi Srivatsan², Yuqing Zhang² and Zachary Wallace³, ¹University of Pittsburgh, Pittsburgh, PA, ²Massachusetts General Hospital, Boston, MA, ³Massachusetts General Hospital, Newton, MA
Background/Purpose: Older adults with ANCA-associated vasculitis (AAV) have distinct clinical presentations and outcomes when compared to younger adults. Despite a high incidence of AAV in…

« Previous Page
1
…
3
4
5
6
7
…
32
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].